Praxis Precision Medicines (PRAX) – Analysts’ Weekly Ratings Updates

Praxis Precision Medicines (NASDAQ: PRAX) recently received a number of ratings updates from brokerages and research firms:

• 6/2/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by TD Cowen.
• 6/2/2026 – Praxis Precision Medicines was given a new $616.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.
• 6/2/2026 – Praxis Precision Medicines had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $650.00 price target on the stock, down from $750.00.
• 6/2/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by BTIG Research. They now have a $810.00 price target on the stock, down from $843.00.
• 6/2/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $374.00 price target on the stock, down from $420.00.
• 6/2/2026 – Praxis Precision Medicines had its price target lowered by Wedbush from $166.00 to $162.00. They now have an “underperform” rating on the stock.
• 6/2/2026 – Praxis Precision Medicines had its price target lowered by Robert W. Baird from $433.00 to $400.00. They now have an “outperform” rating on the stock.
• 6/2/2026 – Praxis Precision Medicines had its price target lowered by HC Wainwright from $1,245.00 to $1,201.00. They now have a “buy” rating on the stock.
• 5/27/2026 – Praxis Precision Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 5/26/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by HC Wainwright. They now have a $1,245.00 price target on the stock.
• 5/20/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by BTIG Research. They now have a $843.00 price target on the stock.
• 5/13/2026 – Praxis Precision Medicines had its price target raised by Truist Financial Corporation from $700.00 to $715.00. They now have a “buy” rating on the stock.
• 5/8/2026 – Praxis Precision Medicines was given a new $420.00 price target by Deutsche Bank Aktiengesellschaft.
• 5/8/2026 – Praxis Precision Medicines had its price target raised by Wedbush from $130.00 to $166.00. They now have an “underperform” rating on the stock.
• 5/8/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by BTIG Research. They now have a $843.00 price target on the stock.
• 5/7/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 4/15/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $437.00 price target on the stock.
• 4/14/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $510.00 price target on the stock.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.